London Daily

Focus on the big picture.
Wednesday, Sep 03, 2025

City analysts come out in support of Glaxo plan

City analysts come out in support of Glaxo plan

Brokers say shares are undervalued compared with New GSK prospects

A growing number of City analysts have come out in support of GlaxoSmithKline’s restructuring plan under chief executive Emma Walmsley despite the efforts of activist investor Elliott to stir up shareholders.

Brokers Morgan Stanley, Liberum, Jefferies and Berenberg issued research notes broadly supportive of the strategy which will split off the consumer arm and focus “new” GSK on its pharmaceuticals and vaccines operations.

All said the current bombed-out share price did not reflect the true value of the business post-restructuring.

However, they stressed that GSK had to build up investors’ confidence in the strength of its pipeline of drugs in development. Key to this will be its June 23 investor day when Walmsley’s team will give more details on prospects for New GSK in the first five years of its life.

Berenberg said patent expiries meant GSK needed to get two “megabuster” new drugs to market by the middle of the decade.

Morgan Stanley said the new five-year targets expected at the event could trigger upgrades to the City’s profit forecasts but warned increased disclosure on the progress in its pipeline was needed.

Several were expecting a dividend cut to fund investment in research and development. Liberum speculated a “part-IPO” might be signalled for the consumer division.

What the analysts said:


Morgan Stanley


Price target 1550p


“We believe the that the new five year targets [unveiled on 23 June] could provide upside to consensus earnings in 2026, but incremental progress in innovation and limited long-term visibility suggest GSK could remain a “show-me” story.”

Points out that the biopharma arm is becoming a more innovation-led business, but largely because established medicines are in decline and some HIV drugs come off patent in 2027-29.

Says the 23 June meeting will focus on four areas:

1) Reprioritising established products

2) Details on how it will grow its ViiV HIV business around its Cabotegravir product

3) Putting into context how innovations in mRNA, highlighted by the Covid crisis, will disrupt GSK’s vaccines business

4) Focusing investors’ minds on six pivotal programmes in its pharmaceuticals R&D pipeline

Liberum


Price target 1700p


Suggests the capital markets event will outline forecast sales growth of “new GSK” at 6% with underlying profit growth at 10% a year for 2021-26. Both of those are slightly ahead of City forecasts.

Expects clarification on how Walmsley plans to split off the consumer arm. Debate is raging around whether it should be through an IPO or a spin-off. Some shareholders are concerned an IPO would be used to raise new money, meaning existing investors get diluted. Liberum argues a “part-IPO” looked increasingly likely.

“We continue to believe the long-term potential of New GSK is underappreciated and reiterate our BUY rating and £17 target price.

Berenberg


Price target 1570p


Expects news on growth outlook for New GSK for the next five or 10 years and on the extent of the proposed 2022 dividend cut - needed to fund R&D spend.

“Clear communication from management will be critical in order to convince many sceptical yet intrigued investors that now is the time to buy.

“We continue to believe there is deep value and view the implied negative pipeline value for GSK as unwarranted; we reiterate our Buy recommendation.”

Looking at how the management’s own performance pay is set, Berenberg predicts five year sales forecasts out to 2026 will be 5% annual growth with operating profit 10% - the latter being higher than the consensus of 8% in the City.

Says that to make up for the patent expiry at the end of 2017 of dolutegravir, an HIV/AIDS retroviral, GSK needs two “megabusters”, indications of which will require 8-10 “shots on goal” in the pipeline. Berenberg has identified “at least four” in phase II or III trials that fit the bill.

The broker assumes a 50% cut in the dividend to pay to bring in new blockbusters.

Jefferies:


Price target 1925p


Predicts dividend will be halved, broadly as expected, but thinks New GSK’s five year growth plan could be bolder than the market has factored in, with bigger sales and profit expectations.

Says a spin-off of the consumer arm is more likely than an IPO. A flotation and fundraiser would put people off holding GSK shares for a year, it says.

Key is to build belief in the pipeline, namely, in its core areas of vaccines, oncology, immunology and infectious diseases including HIV.

Says GSK could raise cash to reinvest in the business by selling off some of the pharma portfolio such as dermatology.

Highlights that its investments in biotech stakes including Vir, CureVac and 23andMe, which is floating soon, are underappreciated.

Newsletter

Related Articles

0:00
0:00
Close
Google Avoids Break-Up in U.S. Antitrust Case as Stocks Rise
Couple celebrates 80th wedding anniversary at assisted living facility in Lancaster
Information Warfare in the Age of AI: How Language Models Become Targets and Tools
The White House on LinkedIn Has Changed Their Profile Picture to Donald Trump
"Insulted the Prophet Muhammad": Woman Burned Alive by Angry Mob in Niger State, Nigeria
Trump Responds to Death Rumors – Announces 'Missile City'
Court of Appeal Allows Asylum Seekers to Remain at Essex Hotel Amid Local Tax Boycott Threats
Germany in Turmoil: Ukrainian Teenage Girl Pushed to Death by Illegal Iraqi Migrant
United Krack down on human rights: Graham Linehan Arrested at Heathrow Over Three X Posts, Hospitalised, Released on Bail with Posting Ban
Asian and Middle Eastern Investors Avoid US Markets
Ray Dalio Warns of US Shift to Autocracy
Eurozone Inflation Rises to 2.1% in August
Russia and China Sign New Gas Pipeline Deal
China's Robotics Industry Fuels Export Surge
Suntory Chairman Resigns After Police Probe
Gold Price Hits New All-Time Record
Von der Leyen's Plane Hit by Suspected Russian GPS Interference in an Incident Believed to Be Caused by Russia or by Pro-Peace or by Anti-Corruption European Activists
UK Fintechs Explore Buying US Banks
Greece Suspends 5% of Schools as Birth Rate Drops
Apollo to Launch $5 Billion Sports Investment Vehicle
Bolsonaro Trial Nears Close Amid US-Brazil Tension
European Banks Push for Lower Cross-Border Barriers
Poland's Offshore Wind Sector Attracts Investors
Nvidia Reveals: Two Mystery Customers Account for About 40% of Revenue
Woody Allen: "I Would Be Happy to Direct Trump Again in a Film"
Pickles are the latest craze among Generation Z in the United States.
Deadline Day Delivers Record £125m Isak Move and Donnarumma to City
Nestlé Removes CEO Laurent Freixe Following Undisclosed Relationship with Subordinate
Giuliani Seriously Injured in Accident – Trump to Award Him the Presidential Medal of Freedom
EU is getting aggressive: Four AfD Candidates Die Unexpectedly Ahead of North Rhine-Westphalia Local Elections
Lula and Putin Hold Strategic BRICS Discussions Ahead of Trump–Putin Summit
WhatsApp is rolling out a feature that looks a lot like Telegram.
Investigations Reveal Rise in ‘Sex-for-Rent’ Listings Across Canada Exploiting Vulnerable Tenants
Chinese and Indian Leaders Pursue Amity Amid Global Shifts
European Union Plans for Ukraine Deployment
ECB Warns Against Inflation Complacency
Concerns Over North Cyprus Casino Development
Shipping Companies Look Beyond Chinese Finance
Rural Exodus Fueling European Wildfires
China Hosts Major Security Meeting
Chinese Police Successfully Recover Family's Savings from Livestream Purchases
Germany Marks a Decade Since Migrant Wave with Divisions, Success Stories, and Political Shifts
Liverpool Defeat Arsenal 1–0 with Szoboszlai Free-Kick to Stay Top of Premier League
Prince Harry and King Charles to Meet in First Reunion After 20 Months
Chinese Stock Market Rally Fueled by Domestic Investors
Israeli Airstrike in Yemen Kills Houthi Prime Minister
Ukrainian Nationalist Politician Andriy Parubiy Assassinated in Lviv
Corporate America Cuts Middle Management as Bosses Take On Triple the Workload
Parents Sue OpenAI After Teen’s Death, Alleging ChatGPT Encouraged Suicide
Amazon Faces Lawsuit Over 'Buy' Label on Digital Streaming Content
×